Lifeboat Foundation

Last week the FDA announced that they have granted permission for the TAME trial. The Targeting Aging with Metformin (TAME) trial is the first human trial specifically looking at an anti-aging drug in humans.

Repurposing An Old Medicine

Metformin is an old drug, first approved in France in 1957, for the treatment of type 2 diabetes and polycystic ovary syndrome (PCOS). However extracts from the French liliac (Galega officinalis), the plant containing a precursor of metformin, has been used to treat frequent urination, a symptom of diabetes, since the Middle Ages. In 2012 in the US about 60 million prescriptions for metformin were written, making metformin the most used antidiabetic drug. Amazingly, every year about 37,000 metric tons of metformin are produced! Metformin is also a super-cheap drug, costing only cents per dose.

Read more

C. elegans roundworm (credit: The Goldstein Lab)

When researchers at The Scripps Research Institute (TSRI) in California administered an antidepressant called mianserin to the Caenorhabditis elegans roundworm in 2007, they discovered the drug increased the lifespan of the “young adulthood” of roundworms by 30–40 per cent.

So, does that mean it will work in humans? Not necessarily. “There are millions of years of evolution between worms and humans,” says TSRI researcher Michael Petrascheck. “We may have done this in worms, but we don’t want people to get the impression they can take the drug we used in our study to extend their own teens or early twenties.”

Read more

In a new study, people who believed negative stereotypes about old age had higher risk of Alzheimer’s.

Read more

This article is based on my skype conversation with Elizabeth Parrish, founder and CEO of BioViva. BioViva is a biotech company in the Seattle area focused on developing gene therapies to mitigate the diseases of aging. Liz is currently experimenting these therapies on herself. Her research was recently covered in a MIT Technology Review article and she did an AMA on Reddit you may want to check out.

Read more

An Immortality Bus campaign report today on CNET from South Carolina and transhumanism discussed. http://www.cnet.com/videos/the-cravecast-visits-the-future-w…an-istvan/ And here’s the original story: http://www.cnet.com/news/the-cravecast-welcomes-the-presiden…he-robots/

The Transhumanist Party candidate called in from the campaign trail and his “Immortality Bus” to help us look forward to 2016… and to 2050.

Read more

Glucosepane is one of the most significant mechanisms of aging and yet very few people are working on it!

As we age skin and blood vessels lose their elasticity. People care too much about the skin and too little about the blood vessels, but that is always the way of it. Appearance first and substance later, if at all. Yet you can live inside an aged skin; beyond the raised risk of skin cancer its damaged state arguably only makes life less pleasant, and the present state of medical science can ensure that the numerous age-related dermatological dysfunctions can be kept to a state of minor inconvenience. Loss of blood vessel elasticity, on the other hand, will steadily destroy your health and then kill you. Arterial stiffening causes remodeling of the cardiovascular system and hypertension. The biological systems that regulate blood pressure become dysfunctional as blood vessels depart from ideal youthful behavior, creating a downward spiral of increasing blood pressure and reactions to that increase. Small blood vessels fail under the strain in ever larger numbers, damaging surrounding tissue. In the brain this damage contributes to age-related cognitive decline by creating countless tiny, unnoticed strokes. Ultimately this process leads to dementia. More important parts of the cardiovascular system are likely to fail first, however, perhaps causing a stroke, or a heart attack, or the slower decline of congestive heart failure.

From what is known today, it is reasonable to propose that the two main culprits driving loss of tissue elasticity are sugary cross-links generated as a byproduct of the normal operation of cellular metabolism and growing numbers of senescent cells. Elasticity is a property of the extracellular matrix, an intricate structure of collagens and other proteins created by cells. Different arrangements of these molecules produce very different structures, ranging from load-bearing tissues such as bone and cartilage to elastic tissues such as skin and blood vessel walls. Disrupting the arrangement and interaction of molecules in the extracellular matrix also disrupts its properties. Persistent cross-links achieve this by linking proteins together and restricting their normal range of motion. Senescent cells, on the other hand, secrete a range of proteins capable of breaking down or remodeling portions of the surrounding extracellular matrix, and altering the behavior of nearby cells for the worse.

Continue reading “Scores of Labs Should be Gearing Up to Work on Glucosepane Cross-Link Breakers, But Are They?” »

Can we end violence? Can we create greater emotional well being and intellectual equality for the greater well being of humanity? Will we be able to keep up with machines? How can we augment our intelligence? Could we cure mental illness? After advancements in aging the next major area of research from a standpoint of eliminating personal and global suffering would be upgrades in intelligence. Transhumanist values at their core want to eliminate suffering and existential risk to people’s lives. With well founded logic, these goals are not completely out of reach, it is possible but as usual, we will have to take the complex issue from many angles and from the standpoint of a systems engineer, but let’s look at some fun stuff before we get into the heavy stuff.

The Benefits of Intelligence Upgrades

Continue reading “Transhumanism Solving Violence and Improving the Human Condition: IQ, EQi, and Intelligence Upgrades” »

Exciting news as another group proposes to explore telomerase therapy for the Cardio Vascular system. This no doubt follows on from DePhino et al work on the P53-telomerase-PCG-1 aging axis work which showed the effects of short telomeres on vascular aging (and other organs) and its direct link to Mitochondrial function and Stem cell Decline via the P53-telomerase-PCG-1 aging axis.

Read more

To most of the scientific community, “anti-aging” is a dirty word.

A medical field historically associated with charlatans and quacks, scientists have strictly restricted the quest for a “longevity pill” to basic research. The paradigm is simple and one-toned: working on model organisms by manipulating different genes and proteins, scientists slowly tease out the molecular mechanisms that lead to — and reverse — signs of aging, with no guarantee that they’ll work in humans.

But it’s been a fruitful search: multiple drug candidates, many already on the market for immune or psychiatric disorders, have consistently delayed age-associated diseases and stretched the lifespan of fruit flies, roundworms and mice. Yet human trials have been far beyond reach — without the FDA acknowledging “aging” as a legitimate target for drug development, researchers have had no way of pitching clinical trials to the regulatory agency.

Read more